[
    {
        "Header Number": "N/A",
        "Title": "Clinical Development",
        "Content": " RAD001 CRAD001C24114 / NCT00767819Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcomas RAP Module 3 \u2013 Detailed statistical methodology Author:  Document type: RAP Documentation Document status: Final 1.0 Release date: 07-Jul-2011Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Novartis \nConfidential \nPage 2 \nRAP Module 3 \n10-Apr-2018 \nRAD001/Afinitor\u00ae \n \nNovartis approval signatures for: \nRAP Module 3 \u2013 Detailed statistical methodology \n \n \n \n \n \n \nSignature \n \nDate \n \n \n \n \n \n \nSignature \n \nDate \n \n",
        "Sub-sections": []
    },
    {
        "Header Number": "1",
        "Title": "Data analysis",
        "Content": "Novartis Confidential Page 4 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  ",
        "Sub-sections": [
            {
                "Header Number": "1.1",
                "Title": "Populations for analysis",
                "Content": " The safety set consisted of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received. Of note, the statement that a patient had no adverse events also constituted a safety assessment. The intent-to-treat (ITT) set consisted of all patients who received at least one dose of study drug and had at least one post-baseline assessment of the primary efficacy variable (target/non-target lesion assessment according to RECIST). Patients without any post-baseline assessment of tumor were included if they were defined as progressive disease based on clinical evaluation. The per-protocol (PP) set consisted of all patients of the intent-to-treat population who did not show any major protocol violations. As major protocol violations were considered those that may have an impact on the study outcome. Criteria that were assumed to have such an impact were defined in a Review Meeting before database lock. ",
                "Sub-sections": []
            },
            {
                "Header Number": "1.2",
                "Title": "Patient demographics/other baseline characteristics",
                "Content": " Demographic and background information were summarized for the ITT set, using frequency distributions for categorical variables and descriptive statistics of mean, standard deviation, minimum, median and maximum for continuous variables. Background information included prior medication, past/current medical conditions, diagnosis and extent of cancer, ECOG performance status and tumor evaluation at baseline. Medical history was coded using MedDRA and was presented by system organ class, and MedDRA preferred term. Separate tables were provided for past medical condition and current medical condition. Prior medications (including prior antineoplastic medications and radiotherapy) were coded according to WHO Drug Reference List (WHO-DRL). Prior medications  were summarized by ATC class and preferred term. ",
                "Sub-sections": []
            },
            {
                "Header Number": "1.3",
                "Title": "Treatments (study drug, rescue medication, other concomitant therapies, compliance)",
                "Content": " Study drug and concomitant therapies were analyzed for the safety set. Study drug Duration of exposure to study drug was defined as the time from start of treatment to the last end date documented in the Study Drug Administration CRF. Duration of exposure was summarized descriptively. Mean daily doses of study drug were calculated including and excluding zero doses for periods of temporary interruption of treatment regardless of whether this was due to safety reasons or patients\u2019 non-compliance. Mean daily doses were summarized descriptively.  The number of dose changes/patients with dose changes (including temporary dose interruption) was presented by reason for dose change by frequency distribution. Permanent treatment discontinuations were analyzed by frequencies. Novartis Confidential Page 5 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  Concomitant medications Concomitant medications were coded according to WHO-DRL and summarized by ATC class and preferred term using frequency tables. ",
                "Sub-sections": []
            },
            {
                "Header Number": "1.4",
                "Title": "Analysis of the primary objective(s)",
                "Content": " ",
                "Sub-sections": [
                    {
                        "Header Number": "1.4.1",
                        "Title": "Variable",
                        "Content": " The primary variable is defined as the proportion of patients in whom a best overall response of complete (CR) or partial (PR) response or stable disease (SD) was observed at 16 weeks according to RECIST (version 1.0, Therasse et al. 2000) based on local radiologic assessments. The best overall response for each patient was determined from the sequence of overall (lesion) responses at Visit 4/Week 8 and Visit 6/Week 16, respectively, according to the following rules (see Post-text supplement 1 to the study protocol): \u2022 CR = at least two determinations of CR at least 4 weeks apart before progression. \u2022 PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR). \u2022 SD = at least one SD assessment > 6 weeks after start of treatment (and not qualifying for CR or PR). \u2022 PD = progression or death due to underlying cancer \u2264 16 weeks after start of treatment (and not qualifying for CR, PR or SD). Patients with symptoms of rapidly progressing disease without radiologic evidence will be classified as progression only when clear evidence of clinical deterioration is available and patient discontinued due to \u2018Disease progression\u2019. Furthermore, patients without radiologic evidence for progression who were prematurely discontinuing from the study for \u2018unsatisfactory therapeutic effect\u2019, \u2018new cancer therapy\u2019 or \u2018death\u2019 (from any reason) will be classified as progression. \u2022 UNK = all other cases (i.e. not qualifying for confirmed CR or PR and without SD after more than 6 weeks or early progression within the first 16 weeks) ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "1.4.2",
                        "Title": "Statistical hypothesis, model, and method of analysis",
                        "Content": " The best overall response rate (CR/PR/SD/PD/UNK) was presented together with the appropriate two-sided confidence interval for the ITT set. Since the one-sided alpha was set to 10%, two-sided 80% confidence intervals were presented. Exact confidence intervals were computed according to the method of Clopper and Pearson. The absolute number of patients showing a best overall response of CR, PR or SD was determined to conclude preliminary activity or non-activity of the study drugs in this patient population according to the rules outlined in CSP section 10.2. Furthermore, the lower limit of the confidence interval was used to support the decision in favor of p0 or p1: if the lower limit of the confidence interval overlapped p0, the hypothesis that p is greater than or equal to p1 could be rejected; on the other side, if the lower limit of the confidence interval excluded p0, the hypothesis that p is greater than or equal to p1 could be accepted. Novartis Confidential Page 6 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "1.4.3",
                        "Title": "Handling of missing values/censoring/discontinuations",
                        "Content": " The derivation of the primary efficacy variable from the sequence of overall lesion responses recorded at each assessment followed the Novartis guidance \u2018Guidelines for Response, Duration of Overall Response, TTF, TTP, Progression-Free Survival and Overall Survival (based on RECIST)\u2019. Subjects not qualifying for confirmed CR or PR and without SD after more than 6 weeks or early progression within the first 12 weeks were classified as \u2018UNK\u2019 for their best overall response. ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "1.4.4",
                        "Title": "Supportive analyses",
                        "Content": " The number and percentage of patients showing a best overall response of CR, PR or SD as well as the number and percentage of patients for each category (CR/PR/SD/PD/UNK) was additionally presented for the per-protocol (PP) set. Additionally, for patients who entered the follow-up period starting after Visit 6/Week 16, the best overall response was determined using all available local tumor assessments. ",
                        "Sub-sections": []
                    }
                ]
            },
            {
                "Header Number": "1.5",
                "Title": "Analysis of secondary objectives",
                "Content": " ",
                "Sub-sections": [
                    {
                        "Header Number": "1.5.1",
                        "Title": "Efficacy (secondary)",
                        "Content": " Secondary efficacy variables were analyzed for the ITT set. Objective response rate (ORR) was defined as the proportion of patients in whom a complete (CR) or partial (PR) response was observed at Visit 6/Week 16 according to RECIST (version 1.0) based on central radiologic review. Absolute and relative frequencies were presented together with the appropriate exact confidence interval. Duration of stable disease (CR, PR or SD) applied only to those patients whose best overall response was CR, PR or SD based on local radiologic assessments and was defined as the time from start of treatment to progression or death from underlying disease. Patients not experiencing progression or death at 16 weeks were censored with the date of their last tumor assessment. Duration of response was explored using the Kaplan-Meier method. The Kaplan-Meier estimate for median duration of response as well as the Kaplan-Meier curve was displayed. Although duration of response (CR or PR) was planned to be analyzed within the protocol, this was changed to reach a more valuable analysis since no patient reached a best overall response of CR or PR. Progression-free survival (PFS) was defined as the time from the date of start of treatment to the date of event defined as the first documented progression or death from any cause. If a patient had not had an event, PFS was censored at the date of the last adequate tumor assessment, which was the date of Visit 6 for the core study phase and the last available tumor assessment for the follow-up phase. PFS was explored by using the Kaplan-Meier method. The Kaplan-Meier estimate for median PFS as well as the Kaplan-Meier curve was displayed. Time to progression (TTP) was defined as the time from the date of start of treatment to the date of event defined as the first documented progression or death from underlying disease. If a patient had not had an event, TTP was censored at the date of the last adequate tumor assessment, which was the date of Visit 6 for the core phase and the last available tumor Novartis Confidential Page 7 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  assessment for the follow-up phase. TTP was explored by using the Kaplan-Meier method. The Kaplan-Meier estimate for median TTP as well as the Kaplan-Meier curve was displayed. Overall survival (OS) was defined as the time from the date of start of treatment to death from any cause. If a patient was not known to have died, OS was censored at the date of the last contact, which was the date of Visit 6 for the core phase and the last available visit for the follow-up phase. OS was explored by using the Kaplan-Meier method. The Kaplan-Meier estimate for median OS as well as the Kaplan-Meier curve was displayed. ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "1.5.2",
                        "Title": "Safety",
                        "Content": " The assessment of safety was based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g. electrocardiogram, vital signs, and special tests) were considered as appropriate. ",
                        "Sub-sections": [
                            {
                                "Header Number": "1.5.2.1",
                                "Title": "Adverse events",
                                "Content": " Adverse events (AE) were summarized by presenting the number and percentage of patients having any adverse event, having an adverse event in each body system and having each individual adverse event. Furthermore, the incidence of AE was summarized by maximum severity, for AE with suspected drug relation, for serious AE, for AE leading to permanent discontinuation of study drug, and for significant AE. As significant (S)AE were defined those (S)AE who \u2022 were suspected to be drug related, \u2022 lead to dose adjustment or temporary interruption, \u2022 lead to permanent discontinuation, \u2022 required concomitant medication/non-drug therapy, and  \u2022 Deaths Any other information collected (e.g. severity or relatedness to study medication) was listed as appropriate. ",
                                "Sub-sections": []
                            },
                            {
                                "Header Number": "1.5.2.2",
                                "Title": "Laboratory values",
                                "Content": " Laboratory data were summarized by presenting summary statistics of raw data and changes from baseline value by visit. Although foreseen in the protocol, notable values were not analyzed since no notable ranges were defined in the protocol. Any statistical tests performed to explore the data were used only to highlight any interesting comparisons that may warrant further consideration. Data from other tests (e.g. electrocardiogram or vital signs) were planned to be listed, notable values were recommended to be flagged (if appropriate), and any other information collected was planned to be listed as appropriate. ",
                                "Sub-sections": []
                            }
                        ]
                    },
                    {
                        "Header Number": "1.5.3",
                        "Title": "Tolerability",
                        "Content": " Not applicable. Novartis Confidential Page 8 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  ",
                        "Sub-sections": []
                    },
                    {
                        "Header Number": "1.5.4",
                        "Title": "Resource utilization",
                        "Content": " Not applicable. ",
                        "Sub-sections": []
                    }
                ]
            },
            {
                "Header Number": "1.6",
                "Title": "Sample size calculation",
                "Content": " The study followed an exact binomial single-stage design in each arm. (A\u2019Hern 2001). Values of P0 and P1 followed the recommendation of the EORTC Soft Tissue and Bone Sarcoma Group\u2019s previous publication evaluating PFS in STS patients treated with 2nd line active and inactive compounds. In arm I (patients with bone and soft tissue sarcoma except for GIST), the study required 36 evaluable subjects to decide whether the proportion responding (best overall response of CR, PR or SD), p, was less than or equal to p0 = 20% or greater than or equal to p1 = 40% (Table 10-1). In arm II or III (patients with GIST after failure or intolerance of 1st and 2nd line treatment with imatinib or sunitinib, and patients with progressive or metastatic alveolar soft part sarcoma (ASPS), respectively), the study required 24 evaluable subjects to decide whether the proportion responding best overall response of CR, PR or SD), p, was less than or equal to p0 = 20% or greater than or equal to p1 = 40%. If the number of responses in arm I was 11 or more, the null hypothesis that p is less than or equal to 20% was to be rejected with a target type I error rate of 10% and an actual error rate of 8.9%. If the number of responses in arm I was 10 or less, the alternative hypothesis that p is greater than or equal to 40% was to be rejected with a target type II error rate of 10% and an actual error rate of 9%. If the number of responses in arm II or arm III, respectively, was 8 or more, the null hypothesis that p is less than or equal to 20% was to be rejected with a target type I error rate of 10% and an actual error rate of 8.9%. If the number of responses in arm II was 7 or less, the alternative hypothesis that p is greater than or equal to 40% was to be rejected with a target type II error of 20% and an actual error rate of 19.2%. The designs were estimated with NCSS Trial and PASS 2002. ",
                "Sub-sections": [
                    {
                        "Header Number": "N/A",
                        "Title": "Table 10-1 Design features for exact binomial single-stage designs",
                        "Content": "  Arm I Arm II Arm III p0 (maximum response proportion of an inactive drug) 20% 20% 20% p1 (minimum response proportion of an active drug 40% 40% 40% Type I error (one-sided test) 10% 10% 10% Type II error (one-sided test) 10% 20% 20% Sample size 36 24 24 Accept inactivity at the end if  \u2264 10 responders \u2264 7 responders \u2264 7 responders Reject inactivity at the end if \u2265 11 responders \u2265 8 responders \u2265 8 responders Actual type I error level 8.9% 8.9% 8.9% Actual type II error level 9.0% 19.2% 19.2% The type I error is the probability of rejecting the hypothesis that p is lower or equal to p0 when this is true. The type II error is the probability of rejecting the hypothesis that p is greater or equal to p1 when this is true. Response was defined as a best overall response of CR, PR or SD. Novartis Confidential Page 9 RAP Module 3 10-Apr-2018 RAD001/Afinitor\u00ae  ",
                        "Sub-sections": []
                    }
                ]
            },
            {
                "Header Number": "1.7",
                "Title": "Power for analysis of critical secondary variables",
                "Content": "",
                "Sub-sections": []
            }
        ]
    }
]